Mediators of Inflammation

Mediators of Inflammation / 2007 / Article

Clinical Study | Open Access

Volume 2007 |Article ID 093726 | https://doi.org/10.1155/2007/93726

Kamel Hamzaoui, Hanene Chelbi, Mariam Kamoun, Imen Ben Dhifallah, Agnes Hamzaoui, "Increased Endothelin-1 Levels of BAL Fluid in Patients with Behçet's Disease", Mediators of Inflammation, vol. 2007, Article ID 093726, 6 pages, 2007. https://doi.org/10.1155/2007/93726

Increased Endothelin-1 Levels of BAL Fluid in Patients with Behçet's Disease

Received24 Nov 2006
Revised13 Jan 2007
Accepted16 Jan 2007
Published15 Mar 2007

Abstract

Objective and background. Pulmonary aneurysms and thrombosis constitute a significant cause of morbidity and mortality in Behçet's disease (BD). Various factors have been studied to explore the pathogenesis of vascular involvement in BD. As endothelin (ET) is known for its potent vasoconstrictor and proinflammatory properties, we supposed that it is involved during the inflammatory process of BD pulmonary vasculitis. Methods. To investigate the role of ET in BD, ET-1 concentrations were measured in bronchoalveolar lavage fluid (BALF) of 18 nonsmoking BD patients with pulmonary manifestations and 12 control subjects. Immunoreactivity of ET-1 was also evaluated in alveolar macrophages (AMs) cytoplasm. Results. ET-1 levels in BD-BALF were significantly higher than those of controls. ET-1 levels were correlated with the number of alveolar macrophages, but not with BAL-CD4/CD8 ratio. ET-1-immunoreactivity was found mainly in AM of BD-BAL. Conclusions. Increased ET-1 production from AM is associated with pulmonary BD manifestations.

References

  1. H. Yazici, S. Yurdakul, V. Hamuryudan, and I. Fresko, “Behçet's syndrome,” in Rheumatology, M. C. Hochberg, J. A. Silman, J. S. Smolen, M. E. Weinblatt, and M. H. Weisman, Eds., pp. 1665–1669, Mosby, London, UK, 3rd edition, 2003. View at: Google Scholar
  2. D. Erkan, Y. Yazici, A. Sanders, D. Trost, and H. Yazici, “Is Hughes-Stovin syndrome Behçet's disease?” Clinical and Experimental Rheumatology, vol. 22, no. 4, supplement 24, pp. S64–S68, 2004. View at: Google Scholar
  3. A. Hamzaoui and K. Hamzaoui, “Pulmonary complications of Behçet's disease and Takayasu's arteritis,” Revue des Maladies Respiratoires, vol. 22, no. 6, part 1, pp. 999–1019, 2005. View at: Publisher Site | Google Scholar
  4. K. Aksu, H. Koçanaogullari, G. Keser et al., “A case of Behçet's disease with pulmonary arterial aneurysm and secondary amyloidosis,” Rheumatology, vol. 41, no. 7, pp. 831–832, 2002. View at: Publisher Site | Google Scholar
  5. K. Terashita, S. Kato, M. Sata, S. Inoue, H. Nakamura, and H. Tomoike, “Increased endothelin-1 levels of BAL fluid in patients with pulmonary sarcoidosis,” Respirology, vol. 11, no. 2, pp. 145–151, 2006. View at: Publisher Site | Google Scholar
  6. C. Odoux, B. Crestani, G. Lebrun et al., “Endothelin-1 secretion by alveolar macrophages in systemic sclerosis,” American Journal of Respiratory and Critical Care Medicine, vol. 156, no. 5, pp. 1429–1435, 1997. View at: Google Scholar
  7. M. Kayikçioglu, K. Aksu, C. Hasdemir et al., “Endothelial functions in Behçet's disease,” Rheumatology International, vol. 26, no. 4, pp. 304–308, 2006. View at: Publisher Site | Google Scholar
  8. A. Gül, “Behçet's disease: an update on the pathogenesis,” Clinical and Experimental Rheumatology, vol. 19, no. 5, supplement 24, pp. S6–S12, 2001. View at: Google Scholar
  9. J. C. Chambers, D. O. Haskard, and J. S. Kooner, “Vascular endothelial function and oxidative stress mechanisms in patients with Behçet's syndrome,” Journal of the American College of Cardiology, vol. 37, no. 2, pp. 517–520, 2001. View at: Publisher Site | Google Scholar
  10. R. Joannides, W. E. Haefeli, L. Linder et al., “Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo,” Circulation, vol. 91, no. 5, pp. 1314–1319, 1995. View at: Google Scholar
  11. A. Örem, Y. E. Yandi, B. Vanizor, G. Çimşit, H. A. Uydu, and M. Malkoç, “The evaluation of autoantibodies against oxidatively modified low-density lipoprotein (LDL), susceptibility of LDL to oxidation, serum lipids and lipid hydroperoxide levels, total antioxidant status, antioxidant enzyme activities, and endothelial dysfunction in patients with Behçet's disease,” Clinical Biochemistry, vol. 35, no. 3, pp. 217–224, 2002. View at: Publisher Site | Google Scholar
  12. A. J. Peacock, K. E. Dawes, A. Shock, A. J. Gray, J. T. Reeves, and G. J. Laurent, “Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblasts,” American Journal of Respiratory Cell and Molecular Biology, vol. 7, no. 5, pp. 492–499, 1992. View at: Google Scholar
  13. C. L. Golden, J. P. Kohler, H. S. Nick, and G. A. Visner, “Effects of vasoactive and inflammatory mediators on endothelin-1 expression in pulmonary endothelial cells,” American Journal of Respiratory Cell and Molecular Biology, vol. 12, no. 5, pp. 503–512, 1995. View at: Google Scholar
  14. L. Guembe and A. C. Villaro, “Immunohistochemical mapping of endothelin in the developing and adult mouse lung,” Journal of Histochemistry and Cytochemistry, vol. 49, no. 10, pp. 1301–1309, 2001. View at: Google Scholar
  15. B. Hocher, A. Schwarz, K. A. Fagan et al., “Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice,” American Journal of Respiratory Cell and Molecular Biology, vol. 23, no. 1, pp. 19–26, 2000. View at: Google Scholar
  16. M. Marini, S. Carpi, A. Bellini, F. Patalano, and S. Mattoli, “Endothelin-1 induces increased fibronectin expression in human bronchial epithelial cells,” Biochemical and Biophysical Research Communications, vol. 220, no. 3, pp. 896–899, 1996. View at: Publisher Site | Google Scholar
  17. B. Wechsler, F. Davatchi, Y. Mizushima et al., “Criteria for diagnosis of Behçet's disease,” Lancet, vol. 335, no. 8697, pp. 1078–1080, 1990. View at: Google Scholar
  18. A. Hamzaoui, H. Ghraïri, J. Ammar, S. Zekri, F. Guemira, and K. Hamzaoui, “IL-18 mRNA expression and IFN-γ induction in bronchoalveolar lavage from Behçet's disease,” Clinical and Experimental Rheumatology, vol. 21, no. 4, supplement 30, pp. S8–S14, 2003. View at: Google Scholar
  19. M. Kraft, W. R. Beam, S. E. Wenzel, M. R. Zamora, R. F. O'Brien, and R. J. Martin, “Blood and bronchoalveolar lavage endothelin-1 levels in nocturnal asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 149, no. 4, pp. 946–952, 1994. View at: Google Scholar
  20. F. Erkan, “Pulmonary involvement in Behçet disease,” Current Opinion in Pulmonary Medicine, vol. 5, no. 5, pp. 314–318, 1999. View at: Publisher Site | Google Scholar
  21. V. Hamuryudan, T. Er, E. Seyahi et al., “Pulmonary artery aneurysms in Behçet syndrome,” The American Journal of Medicine, vol. 117, no. 11, pp. 867–870, 2004. View at: Publisher Site | Google Scholar
  22. U. Schmitz-Huebner and J. Knop, “Evidence for an endothelial cell dysfunction in association with Behçet's disease,” Thrombosis Research, vol. 34, no. 4, pp. 277–285, 1984. View at: Publisher Site | Google Scholar
  23. A. Giaid, R. P. Michel, D. J. Stewart, M. Sheppard, B. Corrin, and Q. Hamid, “Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis,” Lancet, vol. 341, no. 8860, pp. 1550–1554, 1993. View at: Publisher Site | Google Scholar
  24. H. Houman, A. Hamzaoui, I. B. Ghorbal, M. S. Khanfir, M. Feki, and K. Hamzaoui, “Tc1/Tc2 ratio in the inflammatory process in patients with Behçet's disease,” Mediators of Inflammation, vol. 13, no. 4, pp. 247–253, 2004. View at: Publisher Site | Google Scholar
  25. S. Kaneko, N. Suzuki, N. Yamashita et al., “Characterization of T cells specific for an epitope of human 60-kD heat shock protein (hsp) in patients with Behçet's disease (BD) in Japan,” Clinical and Experimental Immunology, vol. 108, no. 2, pp. 204–212, 1997. View at: Publisher Site | Google Scholar
  26. H. Direskeneli, E. Eksioglu-Demiralp, S. Yavuz et al., “T cell responses to 60/65 kDa heat shock protein derived peptides in Turkish patients with Behçet's disease,” Journal of Rheumatology, vol. 27, no. 3, pp. 708–713, 2000. View at: Google Scholar
  27. W.-U. Kim, J.-H. Do, K.-S. Park et al., “Enhanced production of macrophage inhibitory protein-1a in patients with Behçet's disease,” Scandinavian Journal of Rheumatology, vol. 34, no. 2, pp. 129–135, 2005. View at: Publisher Site | Google Scholar
  28. S. Molet, K. Furukawa, A. Maghazechi, Q. Hamid, and A. Giaid, “Chemokine- and cytokine-induced expression of endothelin 1 and endothelin-converting enzyme 1 in endothelial cells,” Journal of Allergy and Clinical Immunology, vol. 105, no. 2, pp. 333–338, 2000. View at: Publisher Site | Google Scholar
  29. M. S. Kurokawa and N. Suzuki, “Behçet's disease,” Clinical and Experimental Medicine, vol. 4, no. 1, pp. 10–20, 2004. View at: Publisher Site | Google Scholar
  30. G. W. Chalmers, K. J. Macleod, S. Sriram et al., “Sputum endothelin-1 is increased in cystic fibrosis and chronic obstructive pulmonary disease,” European Respiratory Journal, vol. 13, no. 6, pp. 1288–1292, 1999. View at: Publisher Site | Google Scholar
  31. M. O. Oztas, M. Onder, M. A. Gurer, N. Bukan, and B. Sancak, “Serum interleukin 18 and tumour necrosis factor-α levels are increased in Behçet's disease,” Clinical and Experimental Dermatology, vol. 30, no. 1, pp. 61–63, 2005. View at: Publisher Site | Google Scholar
  32. E. Bozoglu, A. Dinc, H. Erdem, S. Pay, I. Simsek, and I. H. Kocar, “Vascular endothelial growth factor and monocyte chemoattractant protein-1 in Behçet's patients with venous thrombosis,” Clinical and Experimental Rheumatology, vol. 23, no. 4, supplement 38, pp. S42–S48, 2005. View at: Google Scholar
  33. F. Finsnes, T. Lyberg, G. Christensen, and O. H. Skjønsberg, “Effect of endothelin antagonism on the production of cytokines in eosinophilic airway inflammation,” American Journal of Physiology. Lung Cellular and Molecular Physiology, vol. 280, no. 4, pp. L659–L665, 2001. View at: Google Scholar
  34. M. M. Cerinic and M. B. Kahaleh, “Beauty and the beast. The nitric oxide paradox in systemic sclerosis,” Rheumatology, vol. 41, no. 8, pp. 843–847, 2002. View at: Publisher Site | Google Scholar
  35. J. A. Karasneh, A. H. Hajeer, A. Silman, J. Worthington, W. E. R. Ollier, and A. Gul, “Polymorphisms in the endothelial nitric oxide synthase gene are associated with Behçet's disease,” Rheumatology, vol. 44, no. 5, pp. 614–617, 2005. View at: Publisher Site | Google Scholar
  36. J. U. Kim, H. K. Chang, S. S. Lee et al., “Endothelial nitric oxide synthase gene polymorphisms in Behçet's disease and rheumatic diseases with vasculitis,” Annals of the Rheumatic Diseases, vol. 62, no. 11, pp. 1083–1087, 2003. View at: Publisher Site | Google Scholar
  37. F. Oksel, G. Keser, M. Ozmen et al., “Endothelial nitric oxide synthase gene Glu298Asp polymorphism is associated with Behçet's disease,” Clinical and Experimental Rheumatology, vol. 24, no. 5, supplement 42, pp. S79–S82, 2006. View at: Google Scholar
  38. M. Cukiernik, D. Hileeto, T. Evans, S. Mukherjee, D. Downey, and S. Chakrabarti, “Vascular endothelial growth factor in diabetes induced early retinal abnormalities,” Diabetes Research and Clinical Practice, vol. 65, no. 3, pp. 197–208, 2004. View at: Publisher Site | Google Scholar

Copyright © 2007 Kamel Hamzaoui et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views93
Downloads588
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.